Landmark day for Duchenne as Givinostat approved for use in England

On a landmark day for the Duchenne muscular dystrophy community, we are delighted to share that the National Institute for Health and Care Excellence (NICE) has recommended the treatment givinostat (brand name Duvyzat) for use on the NHS in England. In final draft...

Solid doses first patient on Phase 3 trial

Today, Solid Biosciences announced that the first participant has been dosed in the Phase 3 Impact Duchenne clinical trial, a randomised, double-blind, placebo-controlled study evaluating SGT-003 for Duchenne. Clinical trial sites are currently active in Australia and...

Solid shares update on Inspire Duchenne clinical trial

Solid Biosciences has released an update on its Inspire Duchenne clinical trial, which is investigating the safety, tolerability and efficacy of its gene therapy candidate SGT-003. The Phase 1/2, open-label study has now dosed 23 patients, and expects to have dosed 30...

DMD Care UK cardiac guideline recognised by NICE

On World Duchenne Awareness Day 2025, the Duchenne Research Fund is delighted to share that NICE has recognised the cardiac care guidelines that were created and published by the DMD Care UK programme that we fund. As stated on NICE’s website: “We think...

Update on gene therapy Elevidys

Earlier this month the US Food and Drug Administration (FDA) requested that Sarepta Therapeutics place Elevidys clinical trials on hold, due to safety concerns. The request followed three deaths potentially related to the gene therapy products. The deaths appeared to...

Solid reports positive clinical trial data

Solid Biosciences has shared positive clinical data for the first three patients in its Inspire Duchenne clinical trial. They have been dosed with Solid’s next generation gene therapy, known as SGT-003. Biopsy data at day 90 showed average microdystophin...

NICE approves DRF-funded treatment for Duchenne

New medicine for Duchenne muscular dystrophy, funded by Duchenne Research Fund and patient groups, becomes first approved treatment in the UK for all patients with Duchenne The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on...

John Walton Muscular Dystrophy Research Centre marks 10 years

We were invited to join the celebrations for the John Walton Muscular Dystrophy Research Centre’s 10th anniversary in Newcastle. The late Lord John Walton was a pioneering neurologist who made an enormous impact on muscular dystrophy diagnosis and treatment. The...

Solid expands gene therapy trial

We are pleased to share that Solid Biosciences has seen encouraging early results so far in the clinical trial of its next-generation gene therapy, SGT-003. The study, called Inspire Duchenne, began earlier this year at two sites in the US, and has already expanded to...

World Muscle Society awards 2024 DRF prize

The World Muscle Society has awarded the Duchenne Research Fund prize at the annual WMS international congress, supporting a talented researcher in the Duchenne arena. The winner at the 29th congress in Prague, Czech Republic, in October 2024 was Rebecca Willcocks,...